Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Siener K[original query] |
---|
The burden of influenza-associated respiratory hospitalizations in Bhutan, 2015-2016
Thapa B , Roguski K , Azziz-Baumgartner E , Siener K , Gould P , Jamtsho T , Wangchuk S . Influenza Other Respir Viruses 2018 13 (1) 28-35 BACKGROUND: Influenza burden estimates help provide evidence to support influenza prevention and control programs. In this study, we estimated influenza-associated respiratory hospitalization rates in Bhutan, a country considering influenza vaccine introduction. METHODS: Using real time reverse transcription polymerase chain reaction laboratory results from severe acute respiratory infection (SARI) surveillance, we estimated the proportion of respiratory hospitalizations attributable to influenza each month among patients aged <5, 5-49, and >/=50 years in six Bhutanese districts for 2015 and 2016. We divided the sum of the monthly influenza-attributed hospitalizations by the total of the six district populations to generate age-specific rates for each year. RESULTS: In 2015, 10% of SARI patients tested positive for influenza (64/659) and 18% tested positive (129/736) in 2016. The incidence of influenza-associated hospitalizations among all age groups was 50/100,000 persons (95% confidence interval [CI]: 45-55) in 2015 and 118/100,000 persons (95% CI: 110-127) in 2016. The highest rates were among children <5 years: 182/100,000 (95% CI: 153-210) in 2015 and 532/100,000 (95% CI: 473-591) in 2016. The second highest influenza-associated hospitalization rates were among adults >/=50 years: 110/100,000 (95% CI: 91-130) in 2015 and 193/100,000 (95% CI: 165-221) in 2016. CONCLUSIONS: Influenza viruses were associated with a substantial burden of severe illness requiring hospitalization especially among children and older adults. These findings can be used to understand the potential impact of seasonal influenza vaccination in these age groups. This article is protected by copyright. All rights reserved. |
Building consumer demand for tobacco-cessation products and services: the national tobacco cessation collaborative's consumer demand roundtable
Backinger CL , Thornton-Bullock A , Miner C , Orleans CT , Siener K , DiClemente CC , Phillips TM , Rowden JN , Arkin E . Am J Prev Med 2010 38 S307-11 Of the 43.4 million current smokers in the U.S., 70% say that they want to quit, and over 40% report making at least one serious quit attempt each year.1, 2 But most smokers who try to quit do not use the proven treatments that could double or triple their chances of succeeding.3 Unfortunately, smokers in the groups and populations with the highest smoking prevalence (Native Americans/Alaska Natives, low-income smokers, and those with limited formal education) are the most likely to try to quit, the least likely to use proven treatments, and the most likely to fail in their attempts.4, 5 There is no better way to improve the nation's health and reduce health and healthcare disparities than to reach, with treatments that work, more of the 17 million U.S. smokers who try to quit. | Boosting smokers' success by increasing their awareness of, demand for, access to, and use of effective treatments was recently identified as a priority by the Treating Tobacco Use and Dependence: 2008 Update—Clinical Practice Guideline and previously by the NIH State-of-the-Science Conference on Tobacco Cessation, Prevention, and Control in 2006.3, 6 The National Tobacco Cessation Collaborative (NTCC)'s Consumer Demand Roundtable was created to focus on this priority of building greater demand for tobacco-cessation products and services. Part of the reason for the underuse of science-based treatments is that for decades the public health community has seen smokers as “patients” who are prescribed treatments and told how to quit. With this view, treatments only have to be effective, but not necessarily appealing. But in today's consumer culture, smokers have many options, both proven and unproven. Viewing smokers instead as “consumers” involves seeing them as empowered to make treatment choices. Viewing smokers and quitters as consumers makes it clear that proven treatments must not only be effective, but also engaging and able to produce a positive consumer experience. From this perspective, if we are doing our jobs, quitters should want to use the treatments that work. The fact that treatment use remains low even when proven treatments are offered free of charge or are fully covered by health insurance indicates that we have more work to do. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure